BOSTON SCIENTIFIC CORP
BSXAPI behind this page
BSX Q2 2025 request
Playground key active
/api/financials?ticker=BSX&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 5,061 | 4,120 | +22.8% |
Show Product Lines breakouts |
|||
| Cardiac Rhythm Management [Member] | 590 | 576 | +2.4% |
| Cardiac Rhythm Management [Member] · Non Us | 235 | 224 | +4.9% |
| Cardiac Rhythm Management [Member] · US | 355 | 352 | +0.9% |
| Cardiology [Member] | 2,647 | 2,047 | +29.3% |
| Cardiology [Member] · Non Us | 1,007 | 881 | +14.3% |
| Cardiology [Member] · US | 1,640 | 1,166 | +40.7% |
| Electrophysiology [Member] | 840 | 428 | +96.3% |
| Electrophysiology [Member] · Non Us | 252 | 157 | +60.5% |
| Electrophysiology [Member] · US | 587 | 271 | +116.6% |
| Endoscopy [Member] | 737 | 676 | +9.0% |
| Endoscopy [Member] · Non Us | 281 | 261 | +7.7% |
| Endoscopy [Member] · US | 456 | 415 | +9.9% |
| Interventional Cardiology Therapies | 731 | 665 | +9.9% |
| Interventional Cardiology Therapies · Non Us | 479 | 464 | +3.2% |
| Interventional Cardiology Therapies · US | 252 | 201 | +25.4% |
| Neuromodulation [Member] | 303 | 282 | +7.4% |
| Neuromodulation [Member] · Non Us | 75 | 68 | +10.3% |
| Neuromodulation [Member] · US | 228 | 214 | +6.5% |
| Peripheral Interventions [Member] | 698 | 590 | +18.3% |
| Peripheral Interventions [Member] · Non Us | 296 | 281 | +5.3% |
| Peripheral Interventions [Member] · US | 402 | 308 | +30.5% |
| Urology [Member] | 676 | 525 | +28.8% |
| Urology [Member] · Non Us | 178 | 162 | +9.9% |
| Urology [Member] · US | 499 | 363 | +37.5% |
| Watchman | 486 | 379 | +28.2% |
| Watchman · Non Us | 40 | 36 | +11.1% |
| Watchman · US | 446 | 342 | +30.4% |
Show Business Segments breakouts |
|||
| BSX Reportable Segments [Member] · Asia Pacific | 790 | 670 | +17.9% |
| BSX Reportable Segments [Member] · EMEA | 878 | 822 | +6.8% |
| BSX Reportable Segments [Member] · Latin America and Canada [Member] | 169 | 162 | +4.3% |
| BSX Reportable Segments [Member] · US | 3,224 | 2,466 | +30.7% |
| Cardiovascular | 3,345 | 2,637 | +26.8% |
| Cardiovascular · Non Us | 1,303 | 1,163 | +12.0% |
| Cardiovascular · US | 2,042 | 1,474 | +38.5% |
| MedSurg | 1,716 | 1,483 | +15.7% |
| MedSurg · Non Us | 534 | 491 | +8.8% |
| MedSurg · US | 1,183 | 992 | +19.3% |
Show Geography breakouts |
|||
| Emerging Markets [Member] | 758 | 680 | +11.5% |
| Non Us | 1,837 | 1,654 | +11.1% |
| US | 3,224 | 2,466 | +30.7% |
| Cost of Revenue | 1,637 | 1,270 | +28.9% |
| Gross Profit | 3,424 | 2,850 | +20.1% |
| Selling, General & Administrative | 1,716 | 1,446 | +18.7% |
| Research And Development Expense Excluding Acquired In Process Cost | 526 | 383 | +37.3% |
| Royalty Expense | 14 | 9 | +55.6% |
| Amortization Of Intangible Assets | 225 | 213 | +5.6% |
| Impairment Of Intangible Assets Excluding Goodwill | 46 | 276 | -83.3% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -5 | 2 | -350.0% |
| Restructuring Charges | 83 | 1 | +8200.0% |
| Operating Expenses | 2,605 | 2,330 | +11.8% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 264 | 185 | +42.7% |
| Operating Income | 819 | 520 | +57.5% |
| Interest Expense | -90 | -77 | -16.9% |
| Other Nonoperating Income Expense Net | 213 | -23 | +1026.1% |
| Income Before Taxes | 941 | 420 | +124.0% |
| Income Tax Expense (Benefit) | 146 | 98 | +49.0% |
| Net Income | 795 | 322 | +146.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | 795 | 322 | +146.9% |
| Net Income Loss Attributable To Noncontrolling Interest | -2 | -2 | 0.0% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | -2 | -2 | 0.0% |
| Retained Earnings | 2 | 2 | 0.0% |
| Net Income Loss Available To Common Stockholders Basic | 797 | 324 | +146.0% |
| EPS (Basic) | 0.54 | 0.22 | +145.5% |
| EPS (Diluted) | 0.53 | 0.22 | +140.9% |
| Wtd Avg Shares (Basic) | 1,479.9 | 1,470.6 | +0.6% |
| Wtd Avg Shares (Diluted) | 1,493.5 | 1,484.2 | +0.6% |
| Other Non-Operating Income (Expense) | 122 | -100 | +222.0% |
| Comprehensive Income | 103 | 356 | -71.1% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Designated As Hedging Instrument | -198 | 24 | -925.0% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Hedging Designation breakouts |
|||
| Nondesignated · Other Nonoperating Income Expense | 131 | -31 | +522.6% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 534 | 2,913 | -81.7% |
| Accounts Notes And Loans Receivable Net Current | 2,815 | 2,400 | +17.3% |
| Inventory | 2,861 | 2,608 | +9.7% |
| Prepaid Taxes | 298 | 315 | -5.4% |
| Prepaid Expenses & Other Current Assets | 613 | 756 | -18.9% |
| Total Current Assets | 7,121 | 8,991 | -20.8% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,461 | — | — |
| Goodwill | 18,076 | — | — |
Show Business Segments breakouts |
|||
| Cardiovascular | 10,550 | — | — |
| MedSurg | 7,526 | — | — |
Show Business Acquisition breakouts |
|||
| All Other | 300 | — | — |
| Deferred Tax Assets | 3,778 | 3,801 | -0.6% |
| Other Non-Current Assets | 1,864 | 1,551 | +20.2% |
| Total Assets | 41,559 | 37,108 | +12.0% |
| Operating Lease Right-of-Use Assets | 492 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 7,260 | — | — |
| Current Liabilities | |||
| Debt Current | 480 | — | — |
| Accounts Payable | 962 | 906 | +6.2% |
| Accrued Liabilities | 2,797 | 2,320 | +20.6% |
| Other Liabilities Current | 952 | 770 | +23.6% |
| Total Current Liabilities | 5,190 | 5,576 | -6.9% |
| Deferred Revenue | 313 | 284 | +10.2% |
| Commercial Paper (Q) | — | — | — |
Show Short Term Debt Type breakouts |
|||
| Commercial Paper | 197 | — | — |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 226 | 132 | +71.2% |
| Other Non-Current Liabilities | 2,383 | 1,800 | +32.4% |
| Long-Term Debt (Q) | — | — | — |
Show Long-Term Debt Type breakouts |
|||
| December 2027 Notes | 900 | — | — |
| Financial Lease Obligation | 126 | — | — |
| January 2040 Notes | 300 | — | — |
| June 2025 Notes [Member] | 500 | — | — |
| June 2030 Notes | 1,200 | — | — |
| March 2028 Notes | 344 | — | — |
| March 2028 Senior Notes | 879 | — | — |
| March 2029 Euro Senior Notes | 879 | — | — |
| March 2029 Notes | 272 | — | — |
| March 2031 Notes | 879 | — | — |
| March 2031 Notes 2 | 996 | — | — |
| March 2032 Euro Senior Notes | 1,464 | — | — |
| March 2034 Notes | 586 | — | — |
| March 2034 Notes 2 | 762 | — | — |
| March 2039 Notes | 450 | — | — |
| March 2049 Notes | 650 | — | — |
| November 2035 Notes | 350 | — | — |
| Senior Notes | 11.32 | — | — |
| Operating Lease Liabilities | 440 | 365 | +20.5% |
| Accrued Income Taxes Noncurrent | 387 | 356 | +8.7% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 11,107 | — | — |
| Stockholders' Equity | |||
| Common Stock | 17 | 17 | 0.0% |
| Treasury Stock Value | -2,251 | -2,251 | 0.0% |
| Additional Paid In Capital Common Stock | 21,230 | 20,803 | +2.1% |
| Retained Earnings | 4,144 | 1,639 | +152.8% |
| Accumulated Other Comprehensive Income | -722 | 164 | -540.2% |
| Total Stockholders' Equity | 22,418 | 20,371 | +10.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -17 | -8 | -112.5% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -145 | 159 | -191.2% |
| Accumulated Other Comprehensive Income | -722 | 164 | -540.2% |
| Accumulated Translation Adjustment | -560 | 13 | -4407.7% |
| Minority Interest | 235 | 238 | -1.3% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 22,653 | 20,609 | +9.9% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -722 | 164 | -540.2% |
| Additional Paid In Capital | 21,230 | 20,803 | +2.1% |
| Common Stock | 17 | 17 | 0.0% |
| Noncontrolling Interest | 235 | 238 | -1.3% |
| Parent | 22,418 | 20,371 | +10.0% |
| Retained Earnings | 4,144 | 1,639 | +152.8% |
| Treasury Stock Common | -2,251 | -2,251 | 0.0% |
| Total Liabilities & Equity | 41,559 | 37,108 | +12.0% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 661 | 615 | +7.5% |
| Cash Flow Impact Of Deferred Income Tax Expense Benefit | -49 | 21 | -333.3% |
| Stock-Based Compensation | 149 | 129 | +15.5% |
| Impairment Of Intangible Assets Indefinitelived Excluding Goodwill | 46 | 276 | -83.3% |
| Gain Loss On Investments | -191 | 46 | -515.2% |
| Gain Loss On Investments (Q) | — | — | — |
Show Business Acquisition breakouts |
|||
| Bolt Medical, Inc. | -185 | — | — |
| SoniVie Ltd | -45 | — | — |
| Inventory Step Up Amortization | 118 | — | — |
| Other Operating Activities Cash Flow Statement | 72 | 8 | +800.0% |
| Change in Accounts Receivable | -139 | -228 | +39.0% |
| Change in Inventory | -44 | -219 | +79.9% |
| Increase Decrease In Other Operating Assets | -108 | -126 | +14.3% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -154 | -379 | +59.4% |
| Net Cash from Operations | 1,827 | 977 | +87.0% |
| Investing Activities | |||
| Capital Expenditures | -344 | -334 | -3.0% |
| Payments To Acquire Businesses Net Of Cash Acquired | -1,248 | -95 | -1213.7% |
Show Business Acquisition breakouts |
|||
| All Other | -411 | — | — |
| Proceeds From Payments For Investments And Acquisitions Of Certain Technologies | -110 | -139 | +20.9% |
| Proceeds From Settlements Of Hedge Contracts | 69 | — | — |
| Other Investing Activities | 7 | 12 | -41.7% |
| Net Cash from Investing | -1,626 | -556 | -192.4% |
| Financing Activities | |||
| Payment For Contingent Consideration Liability Financing Activities | -62 | -34 | -82.4% |
| Finance Lease Principal Payments | -42 | -25 | -68.0% |
| Repayments Of Short Term Debt | -1,583 | -504 | -214.1% |
| Proceeds From Issuance Of Senior Long Term Debt | 1,558 | 2,145 | -27.4% |
Show Long-Term Debt Type breakouts |
|||
| 2025 Eurobond Offering SNs | 1.56 | — | — |
| Paymenttonetsharesettleemployeeequityawards | -123 | -80 | -53.8% |
| Proceeds From Stock Plans | 147 | 106 | +38.7% |
| Proceeds From Payments For Other Financing Activities | -1 | -15 | +93.3% |
| Net Cash from Financing | -107 | 1,593 | -106.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 41 | -8 | +612.5% |
| Net Change in Cash | 135 | 2,006 | -93.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 741 | 3,062 | -75.8% |
| Restricted Cash And Cash Equivalents At Carrying Value | 109 | 75 | +45.3% |
| Restricted Cash Equivalents Noncurrent | 98 | 74 | +32.4% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.